cover image: SAUBOIN Economics Immunization approval revised version_HE_STREP_simple_Mod_GAVI

20.500.12592/15zbzg

SAUBOIN Economics Immunization approval revised version_HE_STREP_simple_Mod_GAVI

14 Oct 2016

SAUBOIN Economics Immunization approval revised version_HE_STREP_simple_Mod_GAVI.pptx 14/10/16 Estimates of the potential public health impact and cost-effectiveness of adopting pneumococcal vaccination in the routine immunization programme in African GAVI countries: a modelling study C. [...] in Disease Control Priorities, Third edition, 2016 2 1 Deaths (%) 14/10/16 Objectives To estimate the potential public health impact and cost-effectiveness of pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) versus no vaccination in 36 African GAVI countries 3 Methods: Model structure •  A decision-tree model was used to assess the vaccine impact in children u. [...] •  Limitations in this study are related to the limitations from the original estimates of disease incidence and costs. [...] ISPPD 2016 conference, Abstract 143 11 Conclusions •  The implementation of PHiD-CV is projected to have a substantial public health impact •  The impact on the pneumonia burden would be the largest. [...] Editorial support of the related abstract were provided respectively by Abdelilah Ibrahimi (XPE Pharma & Science, on behalf of GSK Vaccines) All Authors are employees of the GSK group of companies and hold shares in the GSK group of companies as part of their employee remuneration.

Authors

Pascal Ndiaye

Pages
7
Published in
Ghana

Tables